scholarly journals Combination treatment with an ETA-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant nephropathy in a 'Fisher-to-Lewis' rat model

2002 ◽  
Vol 17 (5) ◽  
pp. 780-787 ◽  
Author(s):  
J. Adams
Keyword(s):  
Rat Model ◽  
Combination Treatment ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Lewis Rat ◽  
Eta Receptor

scholarly journals Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure

Circulation ◽  
2001 ◽  
Vol 103 (1) ◽  
pp. 148-154 ◽  
Author(s):  
Shokei Kim ◽  
Minoru Yoshiyama ◽  
Yasukatsu Izumi ◽  
Hitomi Kawano ◽  
Manabu Kimoto ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Function ◽  
Cardiac Remodeling ◽  
Rat Heart ◽  
Angiotensin Receptor Blocker ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Receptor

A Combination Treatment of Raloxifene and Vitamin D Enhances Bone-to-Tendon Healing of the Rotator Cuff in a Rat Model

2020 ◽  
Vol 48 (9) ◽  
pp. 2161-2169
Author(s):  
Dong Min Kim ◽  
In Kyoung Shim ◽  
Myung Jin Shin ◽  
Jae Hee Choi ◽  
Yu Na Lee ◽  
...  
Keyword(s):  
Vitamin D ◽  
Rotator Cuff ◽  
Bone Healing ◽  
Rat Model ◽  
Combination Treatment ◽  
Biomechanical Testing ◽  
Female Rats ◽  
Muscle Quality ◽  
Control Group ◽  
The Mean

Background: Tearing and degeneration of the rotator cuff at the tendon-to-bone junction are common in adults aged ≥50 years. Few studies have reported on the relationship between estrogen and the rotator cuff enthesis. In addition to preventing bone loss, selective estrogen receptor modulators have been shown to improve tendon and muscle quality. Purpose: To evaluate the effects of raloxifene (RLX) and vitamin D on rotator cuff tendon-to-bone healing in a rat model. Study Design: Controlled laboratory study. Methods: A total of 29 female rats (58 shoulders) were assigned to 4 groups: (1) control group, (2) ovariectomy (OVX)–only group, (3) no RLX group (OVX and rotator cuff repair [RCR]), and (4) RLX group (OVX, RCR, and RLX). Rats that did not undergo rotator cuff tear (RCT) surgery were divided into the control and OVX-only groups according to OVX surgery. Rats that underwent RCT surgery and RCR were divided into the no RLX and RLX groups according to RLX and vitamin D administration. An estrogen-deficient state was induced by OVX at 12 weeks of age. Bone mineral density (BMD) and trabecular bone characteristics were measured by micro–computed tomography, and healing of the tendon-to-bone junction was evaluated by biomechanical testing, histomorphometry, and micro–magnetic resonance imaging (MRI). Results: The mean final body weight (BW; 461.6 ± 47.3 g) of the OVX-only group was significantly higher and BMD (0.25 ± 0.07 g/cm3) was significantly lower ( P < .001) than the mean final BW (338.5 ± 35.1 g) and BMD (0.48 ± 0.05 g/cm3) of the control group. In contrast, the RLX group showed that the BW (369.6 ± 35.8 g) and BMD (0.41 ± 0.08 g/cm3) were not significantly different from the control group. The RLX group had a significantly higher histomorphometric total score (8.50 ± 1.05) than the no RLX group (4.83 ± 2.48). On biomechanical testing, the RLX group (29.7 ± 9.1 N) showed a significantly higher load to failure than the no RLX group (19.4 ± 8.8 N). On micro-MRI, the RLX group had a more homogeneous low signal and tendon continuity than the no RLX group. Conclusion: The combination treatment of RLX and vitamin D prevented a decrease in local BMD (greater tuberosity of the proximal humerus) and enhanced tendon-to-bone healing of the rotator cuff in a rat model. Clinical Relevance: This study induced an estrogen-deficient state similar to the human postmenopausal state and used drugs that are actually being prescribed in a clinical situation.

scholarly journals Effects of the AT1 receptor blocker losartan and the calcium channel blocker benidipine on the accumulation of lipids in the kidney of a rat model of metabolic syndrome

2010 ◽  
Vol 33 (3) ◽  
pp. 263-268 ◽  
Author(s):  
Nobukazu Ishizaka ◽  
Makiko Hongo ◽  
Gen Matsuzaki ◽  
Kyoko Furuta ◽  
Kan Saito ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Rat Model ◽  
Channel Blocker ◽  
At1 Receptor ◽  
Receptor Blocker ◽  
At1 Receptor Blocker ◽  
Accumulation Of Lipids

scholarly journals Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

2020 ◽  
Vol 31 (9) ◽  
pp. 1941-1943 ◽  
Author(s):  
Jan Wysocki ◽  
Enrique Lores ◽  
Minghao Ye ◽  
Maria Jose Soler ◽  
Daniel Batlle
Keyword(s):  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Ang Ii

Protective Effects of Statin and Angiotensin Receptor Blocker in a Rat Model of Doxorubicin- and Trastuzumab-Induced Cardiomyopathy

2020 ◽  
Vol 33 (10) ◽  
pp. 1253-1263
Author(s):  
Dong-Hyuk Cho ◽  
I-Rang Lim ◽  
Jong-Ho Kim ◽  
Mi-Na Kim ◽  
Yong-Hyun Kim ◽  
...  
Keyword(s):  
Rat Model ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Protective Effects ◽  
Angiotensin Receptor

P18 Beta-blocker/ACE-inhibitor combination treatment in mdx mice

2012 ◽  
Vol 22 ◽  
pp. S12
Author(s):  
A. Blain ◽  
E. Greally ◽  
G. MacGowan ◽  
S. Laval ◽  
A. Blamire ◽  
...  
Keyword(s):  
Combination Treatment ◽  
Beta Blocker ◽  
Ace Inhibitor ◽  
Mdx Mice ◽  
Inhibitor Combination

Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats

2011 ◽  
Vol 300 (6) ◽  
pp. G1094-G1104 ◽  
Author(s):  
Kosuke Kaji ◽  
Hitoshi Yoshiji ◽  
Mitsuteru Kitade ◽  
Yasuhide Ikenaka ◽  
Ryuichi Noguchi ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Amino Acid ◽  
Angiotensin Ii ◽  
Liver Fibrosis ◽  
Combination Treatment ◽  
Iron Chelator ◽  
Receptor Blocker ◽  
Type I ◽  
Oral Iron Chelator

Angiotensin II type I receptor blocker and iron chelator reportedly exert suppressive effects on nonalcoholic steatohepatitis (NASH) progression, including liver fibrosis and hepatocarcinogenesis. The aim of this study was to elucidate the combined effect of losartan (LOS), an angiotensin II type I receptor blocker, and deferasirox (DSX), a newly developed oral iron chelator, on the progression of NASH in rats. To induce NASH, F344 rats were fed a choline-deficient l-amino acid-defined diet for 12 wk, and the effects of LOS and DSX at clinically comparable low doses were elucidated in conjunction with oxidative stress, neovascularization, and hepatic stellate cells (HSC) activation, all known to play important roles in the progression of NASH. Treatment with both LOS and DSX suppressed choline-deficient l-amino acid-defined diet-induced liver fibrosis development and hepatocarcinogenesis. This combination treatment exerted a stronger inhibitory effect compared with treatment with a single agent. These inhibitory effects occurred almost concurrently with the suppression of oxidative stress, neovascularization, and HSC activation. Our in vitro study demonstrated that LOS and DSX inhibited angiotensin II-induced proliferation, transforming growth factor-β1 expression of activated HSC, and in vitro angiogenesis. These results indicated that dual inhibition by combined treatment of LOS and DSX attenuated the progression of NASH. Since both agents are widely used in clinical practice, this combination therapy may represent a potential new strategy against NASH in the near future.

Sign in / Sign up

Export Citation Format

Share Document